Boston Scientific Co. (NYSE:BSX) Shares Acquired by APG Asset Management N.V.

APG Asset Management N.V. increased its holdings in Boston Scientific Co. (NYSE:BSX) by 31.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,292,296 shares of the medical equipment provider’s stock after acquiring an additional 310,101 shares during the quarter. APG Asset Management N.V. owned approximately 0.09% of Boston Scientific worth $92,857,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of BSX. CVA Family Office LLC increased its stake in Boston Scientific by 7.4% in the second quarter. CVA Family Office LLC now owns 1,909 shares of the medical equipment provider’s stock valued at $147,000 after purchasing an additional 131 shares during the period. International Assets Investment Management LLC increased its position in Boston Scientific by 0.6% in the 2nd quarter. International Assets Investment Management LLC now owns 22,596 shares of the medical equipment provider’s stock valued at $1,740,000 after acquiring an additional 139 shares during the period. ST Germain D J Co. Inc. raised its stake in Boston Scientific by 8.0% during the 2nd quarter. ST Germain D J Co. Inc. now owns 1,923 shares of the medical equipment provider’s stock valued at $148,000 after acquiring an additional 143 shares during the last quarter. Pinnacle Associates Ltd. lifted its position in Boston Scientific by 2.0% during the 1st quarter. Pinnacle Associates Ltd. now owns 7,478 shares of the medical equipment provider’s stock worth $512,000 after acquiring an additional 148 shares during the period. Finally, Transcend Capital Advisors LLC grew its stake in shares of Boston Scientific by 2.2% in the 2nd quarter. Transcend Capital Advisors LLC now owns 6,773 shares of the medical equipment provider’s stock valued at $522,000 after purchasing an additional 148 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Buying and Selling

In other Boston Scientific news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $74.12, for a total transaction of $517,579.96. Following the sale, the executive vice president now directly owns 40,188 shares of the company’s stock, valued at approximately $2,978,734.56. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 20,949 shares of company stock worth $1,627,877. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Stock Performance

Shares of BSX opened at $83.08 on Friday. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $84.89. The stock has a market cap of $121.89 billion, a P/E ratio of 69.82, a PEG ratio of 2.78 and a beta of 0.79. The company has a current ratio of 1.61, a quick ratio of 1.14 and a debt-to-equity ratio of 0.44. The company has a 50-day moving average of $79.06 and a two-hundred day moving average of $75.02.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.58 by $0.04. The firm had revenue of $4.12 billion for the quarter, compared to analyst estimates of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. Boston Scientific’s revenue was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 EPS. As a group, research analysts predict that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Analysts Set New Price Targets

BSX has been the subject of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 price target on shares of Boston Scientific in a report on Thursday, July 25th. Barclays lifted their target price on shares of Boston Scientific from $78.00 to $86.00 and gave the company an “overweight” rating in a report on Thursday, August 22nd. The Goldman Sachs Group began coverage on shares of Boston Scientific in a research note on Thursday, May 30th. They set a “buy” rating and a $90.00 price target on the stock. TD Cowen raised their price objective on shares of Boston Scientific from $77.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on Boston Scientific from $73.00 to $78.00 and gave the stock a “hold” rating in a research report on Thursday, July 25th. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has an average rating of “Moderate Buy” and an average price target of $86.65.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.